Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF 3.425
-0.345 (-9.15%)
Mar 13, 2026, 3:59 PM CET
Molecular Partners AG Employees
Molecular Partners AG had 153 employees as of June 30, 2025. The number of employees decreased by 6 or -3.47% since the number was reported on December 31, 2024.
Employees
153
Change
-6
Growth
-3.47%
Revenue / Employee
n/a
Profits / Employee
-378.83K CHF
Market Cap
140.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 153 | -6 | -3.47% |
| Dec 31, 2024 | 159 | -9 | -5.37% |
| Dec 31, 2023 | 168 | -8 | -4.45% |
| Dec 31, 2022 | 175 | 12 | 7.41% |
| Dec 31, 2021 | 163 | 18 | 12.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Basilea Pharmaceutica AG | 189 |
| Santhera Pharmaceuticals Holding AG | 79 |
| BioVersys AG | 29 |
| Newron Pharmaceuticals | 22 |
| Xlife Sciences AG | 17 |
| Addex Therapeutics | 2 |
Molecular Partners AG News
- 19 hours ago - Molecular Partners Reports Highlights and Financial Results for Full Year 2025 - GlobeNewsWire
- 15 days ago - Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript - Seeking Alpha
- 5 weeks ago - Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 - GlobeNewsWire
- 2 months ago - Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 4 months ago - Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript - Seeking Alpha